ArticleCell reports2014
Expression quantitative trait loci and receptor pharmacology implicate Arg1 and the GABA-A receptor as therapeutic targets in neuroblastoma.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- Purification and characterization of arginase from a new Aspergillus niger AUMC16187 isolate from sandy soil.Archives of microbiology · 2026Article
- Myeloid-targeting immunotherapies overcome inhibitory barriers in immune-evasive neuroblastoma.The Journal of experimental medicine · 2025Article
- Neurotransmitter power plays: the synaptic communication nexus shaping brain cancer.Acta neuropathologica communications · 2025Review
- GABA and astrocytic cholesterol determine the lipid environment of GABACommunications biology · 2025Article
- Conditional Activation of c-MYC in Distinct Catecholaminergic Cells Drives Development of Neuroblastoma or Somatostatinoma.Cancer research · 2025Article
- The heterogeneity of neutrophils in cancer and its implication for therapeutic targeting.Nature immunology · 2025Article
- Emerging frontiers in epigenetic-targeted therapeutics for pediatric neuroblastoma.Frontiers in immunology · 2025Review
- Targeting the glutamine-arginine-proline metabolism axis in cancer.Journal of enzyme inhibition and medicinal chemistry · 2024Review
- Pathophysiology of Arginases in Cancer and Efforts in Their Pharmacological Inhibition.International journal of molecular sciences · 2024Review
- The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis.Nature communications · 2024Article
- Amino acid metabolism in health and disease.Signal transduction and targeted therapy · 2023Review
- Regulated Arginine Metabolism in Immunopathogenesis of a Wide Range of Diseases: Is There a Way to Pass between Scylla and Charybdis?Current issues in molecular biology · 2023Review
- Virtual Screening for FDA-Approved Drugs That Selectively Inhibit Arginase Type 1 and 2.Molecules (Basel, Switzerland) · 2022Article
- Therapeutically leveraging GABAExperimental biology and medicine (Maywood, N.J.) · 2021Review
- A Targeted Bioinformatics Assessment of Adrenocortical Carcinoma Reveals Prognostic Implications of GABA System Gene Expression.International journal of molecular sciences · 2020Article
- Polyamines and related signaling pathways in cancer.Cancer cell international · 2020Review
- Distinct diagnostic and prognostic values of γ-aminobutyric acid type A receptor family genes in patients with colon adenocarcinoma.Oncology letters · 2020Article
- Two Receptors, Two Isoforms, Two Cancers: Comprehensive Analysis of KIT and TrkA Expression in Neuroblastoma and Acute Myeloid Leukemia.Frontiers in oncology · 2019Article
- Polyamine synthesis as a target ofThe Journal of biological chemistry · 2018Review
- γ-Aminobutyric acid inhibits the proliferation and increases oxaliplatin sensitivity in human colon cancer cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 6 institutions in 1 country.
Christopher S HackettBiomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Neurology, University of California, San Francisco, San Francisco, CA 94143, USA.
David A QuigleyHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA.
Robyn A WongDepartment of Neurology, University of California, San Francisco, San Francisco, CA 94143, USA.
Justin ChenBiomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Neurology, University of California, San Francisco, San Francisco, CA 94143, USA.
Christine ChengDepartment of Neurology, University of California, San Francisco, San Francisco, CA 94143, USA.
Young K SongOncogenomics Section, Pediatric Oncology Branch, National Cancer Institute, Gaithersburg, MD 20877, USA.
Jun S WeiOncogenomics Section, Pediatric Oncology Branch, National Cancer Institute, Gaithersburg, MD 20877, USA.
Ludmila PawlikowskaDepartment of Anesthesia, University of California, San Francisco, San Francisco, CA 94143, USA; Institute for Human Genetics, University of California, San Francisco, San Francisco, CA 94143, USA.
Yun BaoDepartment of Neurology, University of California, San Francisco, San Francisco, CA 94143, USA.
David D GoldenbergDepartment of Neurology, University of California, San Francisco, San Francisco, CA 94143, USA.
Kim NguyenDepartment of Neurology, University of California, San Francisco, San Francisco, CA 94143, USA.
W Clay GustafsonDepartment of Pediatrics, University of California, San Francisco, San Francisco, CA 94143, USA.
Sundari K RallapalliDepartments of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI 53211, USA.
Yoon-Jae ChoDepartment of Neurology, Stanford University School of Medicine, Stanford, CA 94305, USA.
James M CookDepartments of Chemistry and Biochemistry, University of Wisconsin-Milwaukee, Milwaukee, WI 53211, USA.
Serguei KozlovMouse Cancer Genetics Program, Center for Advanced Preclinical Research, National Cancer Institute, Frederick, MD 21702, USA.
Jian-Hua MaoDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA 94143, USA.
Terry Van DykeMouse Cancer Genetics Program, Center for Advanced Preclinical Research, National Cancer Institute, Frederick, MD 21702, USA.
Pui-Yan KwokInstitute for Human Genetics, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Dermatology, University of California, San Francisco, San Francisco, CA 94143, USA; Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA 94143, USA.
Javed KhanOncogenomics Section, Pediatric Oncology Branch, National Cancer Institute, Gaithersburg, MD 20877, USA.
Allan BalmainHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94143, USA.
QiWen FanDepartment of Neurology, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address: qiwen.fan@ucsf.edu.
William A WeissDepartment of Neurology, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Pediatrics, University of California, San Francisco, San Francisco, CA 94143, USA; Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address: waweiss@gmail.com.
University of California, San Francisco · USNational Cancer Institute · USUniversity of Wisconsin–Milwaukee · USCancer Genetics (United States) · USStanford University · USUCSF Helen Diller Family Comprehensive Cancer Center · US
Funding
Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jennifer Leigh Clarke · 1999 to 2026
$209.7MSELECTIVE ANXIOLYTICS VIA BZR SUBTYPE SPECIFIC LIGANDSR01MH046851 · NIMH · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 1991 to 2010
$4.4MMurine Neuroblastoma Models for Preclinical TherapeuticsR01CA102321 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WEISS, WILLIAM A · 2003 to 2016
$3.4MDevelopment of new drugs for asthma by targeting GABA(A) receptors in the lungR01HL118561 · NHLBI · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 2014 to 2017
$2.0MDesign of New Therapeutic Agents to Treat SchizophreniaR01MH096463 · NIMH · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 2013 to 2017
$1.9MModifiers of Tumor Susceptibility in Murine NeuroblastomaR01NS055750 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WEISS, WILLIAM A · 2008 to 2012
$1.8MSynthesis of Alpha2/Alpha3 GABA Agonists to Treat Neuropathic PainR01NS076517 · NINDS · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 2012 to 2015
$1.3MGenetic network analysis of cancer targetsU01CA176287 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WEISS, WILLIAM A · 2013 to 2016
$1.2MBlockade of p53 and Aurora A in Therapy Resistant NeuroblastomaK08NS079485 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GUSTAFSON, WILLIAM CLAY · 2012 to 2014
$552kNCI NIH HHS P30 CA082103NCI NIH HHS P30CA82103NCI NIH HHS R01 CA102321NCI NIH HHS R01CA102321NCI NIH HHS U01 CA176287NCI NIH HHS U01CA176287NHLBI NIH HHS R01 HL118561NIMH NIH HHS MH096463NIMH NIH HHS R01 MH046851NIMH NIH HHS R01MH046851NIMH NIH HHS R01 MH096463NINDS NIH HHS K08 NS079485NINDS NIH HHS NS076517NINDS NIH HHS R01 NS055750NINDS NIH HHS R01NS055750NINDS NIH HHS R01 NS076517
Abstract
The development of targeted therapeutics for neuroblastoma, the third most common tumor in children, has been limited by a poor understanding of growth signaling mechanisms unique to the peripheral nerve precursors from which tumors arise. In this study, we combined genetics with gene-expression analysis in the peripheral sympathetic nervous system to implicate arginase 1 and GABA signaling in tumor formation in vivo. In human neuroblastoma cells, either blockade of ARG1 or benzodiazepine-mediated activation of GABA-A receptors induced apoptosis and inhibited mitogenic signaling through AKT and MAPK. These results suggest that ARG1 and GABA influence both neural development and neuroblastoma and that benzodiazepines in clinical use may have potential applications for neuroblastoma therapy.
Indexed as
Molecular Targeted TherapyAnimalsApoptosisArginaseBrain NeoplasmsCell Line, TumorCell SurvivalChromosomes, Mammaliangamma-Aminobutyric AcidGene Expression Regulation, NeoplasticGenetic Association StudiesGenetic LinkageGenetic Predisposition to DiseaseHumansMiceNeuroblastomaArginasegamma-Aminobutyric AcidReceptors, GABA-A
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.